UCB’s Fintepla oral seizure treatment receives FDA approval
The drug has received the agency’s seal of approval to treat seizures associated with difficult-to-treat seizures associated with Lennox-Gastaut syndrome.
The drug has received the agency’s seal of approval to treat seizures associated with difficult-to-treat seizures associated with Lennox-Gastaut syndrome.
The companies plan to work on developing personalized care solutions via digital pathology to come up with treatment options for patients with solid tumors.
A new study will seek to understand the body’s response to the Nipah virus in order to support development of vaccines.